By Colin Kellaher
Clinical-stage biotechnology company Galecto is scrapping its lead product candidate following the failure of a Phase 2b study in the chronic lung disease idiopathic pulmonary fibrosis, or IPF.
The Boston company on Tuesday said the study evaluating the safety and efficacy of inhaled GB0139 for the treatment of IPF missed…
Read the full article here
